Evidence map›Paper›PMID 32057296›Full record

ArticleeLife2020

Functional heterogeneity of lymphocytic patterns in primary melanoma dissected through single-cell multiplexing.

Francesca Maria Bosisio, Asier Antoranz, Yannick van Herck, Maddalena Maria Bolognesi, Lukas Marcelis, Clizia Chinello, Jasper Wouters, Fulvio Magni, Leonidas Alexopoulos, Marguerite Stas and 4 more

Open access · goldAbstract read
In one paragraph

Article in eLife, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 61 citations in OpenAlex.

  1. Spatial proteomics: technical evolution and applications in cancer research.Frontiers in cell and developmental biology · 2026
    Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Single-Cell Analysis in Immuno-Oncology.International journal of molecular sciences · 2023
    Review
  12. Article
  13. Article
  14. PD-1Cancers · 2023
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Francesca Maria Bosisio *Laboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.ORCID 0000-0002-8874-2003
Asier Antoranz *ProtATonce Ltd, Athens, Greece.
Yannick van HerckLaboratory of Experimental Oncology, KU Leuven, Leuven, Belgium.
Maddalena Maria BolognesiPathology, Department of Medicine & Surgery, Università degli studi di Milano-Bicocca, Milan, Italy.
Lukas MarcelisLaboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.ORCID 0000-0002-5446-1801
Clizia ChinelloPathology, Department of Medicine & Surgery, Università degli studi di Milano-Bicocca, Milan, Italy.
Jasper WoutersLaboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.ORCID 0000-0002-7129-2990
Fulvio MagniPathology, Department of Medicine & Surgery, Università degli studi di Milano-Bicocca, Milan, Italy.
Leonidas AlexopoulosProtATonce Ltd, Athens, Greece.
Marguerite StasDepartment of Surgical Oncology, KU Leuven, Leuven, Belgium.
Veerle BoecxstaensDepartment of Surgical Oncology, KU Leuven, Leuven, Belgium.
Oliver BechterLaboratory of Experimental Oncology, KU Leuven, Leuven, Belgium.
Giorgio CattorettiPathology, Department of Medicine & Surgery, Università degli studi di Milano-Bicocca, Milan, Italy.ORCID 0000-0003-3799-3221
Joost van den OordLaboratory of Translational Cell and Tissue Research, KU Leuven, Leuven, Belgium.
KU Leuven · BEUniversity of Milano-Bicocca · ITNational Technical University of Athens · GR

Funding

BEL114054 HGS1006-C1121Horizon 2020 Framework Programme 642295Horizon 2020 Framework Programme 675585University of Milano-Bicocca BEL114054 HGS1006-C1121
6 · The paper itself

Abstract

In melanoma, the lymphocytic infiltrate is a prognostic parameter classified morphologically into 'brisk', 'non-brisk' and 'absent' entailing a functional association that has never been proved. Recently, it has been shown that lymphocytic populations can be very heterogeneous, and that anti-PD-1 immunotherapy supports activated T cells. Here, we characterize the immune landscape in primary melanoma by high-dimensional single-cell multiplex analysis in tissue sections (MILAN technique) followed by image analysis, RT-PCR and shotgun proteomics. We observed that the brisk and non-brisk patterns are heterogeneous functional categories that can be further sub-classified into active, transitional or exhausted. The classification of primary melanomas based on the functional paradigm also shows correlation with spontaneous regression, and an improved prognostic value when compared to that of the brisk classification. Finally, the main inflammatory cell subpopulations that are present in the microenvironment associated with activation and exhaustion and their spatial relationships are described using neighbourhood analysis.

Indexed as

HumansLymphocytes, Tumor-InfiltratingMelanomaSingle-Cell AnalysisSkin NeoplasmsTumor Microenvironmentbriskcancer biologyhumanmelanomamicroenvironmentmultiplexTILstumor-infiltrating lymphocytes

Identifiers

PMID32057296
PMCPMC7053517
OpenAlexW3006606880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.